Adjuvant therapy with rituximab appears to be effective but risky in refractory autoimmune bullous skin diseases
- 8 Downloads
KeywordsPneumonia Pulmonary Embolism Clinical Response Adjuvant Therapy Blindness
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 1.Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M.Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. British Journal of Dermatology 156: 352-356, No. 2, Feb 2007Google Scholar
© Adis International limited or Adis Data Information BV 2007